Tolerance to allogeneic and to xenogeneic heart grafts provided by thymectomy of adult mice combined with donor cell and cyclophosphamide inoculation

Transplantation
I Y ChernyakhovskayaL N Fontalin

Abstract

A new method of induction of tolerance to allogeneic and to xenogeneic cells is presented. It includes thymectomy of adult mice followed 1 month later by the injection of 1 X 10(8) spleen cells i.v. and i.p. administration of 200 mg of cyclophosphamide per kg 1 day after cells. This method induced prolonged survival of heterotopically transplanted neonatal C57BL/6 murine heart grafts (more than 8 months) and of August rat heart grafts (more than 2 months) in CBA mice. Tolerance to allo- or xenoantigens was formed at the cell level. Experimental animals did not produce allo- or xenohemagglutinins after graft implantation. Spleen cells of mice with surviving C57BL/6 heart grafts did not respond to C57BL/6 cells in mixed lymphocyte culture (MLC) reaction. Lymphoid cell chimerism was not observed in animals tolerant to alloantigens.

Citations

Jul 1, 1988·Biulleten' eksperimental'noĭ biologii i meditsiny·I Iu CherniakhovskaiaL N Fontalin
Dec 1, 1985·Biulleten' eksperimental'noĭ biologii i meditsiny·I V Liadova, I Iu Cherniakhovskaia
Jun 1, 1988·Biulleten' eksperimental'noĭ biologii i meditsiny·I Iu CherniakhovskaiaL N Fontalin
Nov 1, 1996·Biulleten' eksperimental'noĭ biologii i meditsiny·N V KobetsI Iu Cherniakhovskaia
Sep 16, 2004·Springer Seminars in Immunopathology·Tatyana Prigozhina, Shimon Slavin
Jan 1, 1987·Immunology Today·S Slavin
Jul 22, 1998·Immunology Letters·I N ChernishovaE V Sidorova

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.